TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
HHS announced an updated National Plan to Address Alzheimer’s Disease and Related Dementias, replacing six historical goals with four focused on risk reduction, prevention and treatment, care, and caregiver support. Related federal initiatives include up to $48.8 million in ARPA-H projects and a new FDA prevention accelerator; details on implementation and results remain to come.
The Department of Health and Human Services announced an updated National Plan to Address Alzheimer’s Disease and Related Dementias on Thursday, setting four goals around dementia risk reduction, prevention and treatment, care, and caregiver support. The update is accompanied by federal research and prevention initiatives, including up to $48.8 million in ARPA-H projects and a new FDA program focused on preventing or delaying cognitive decline.
The revised plan replaces six historical goals with four: promoting dementia risk reduction; accelerating ways to prevent and treat Alzheimer’s and dementia; adding dementia care components; and strengthening support for caregivers. HHS said the plan emphasizes reducing dementia risk across a person’s lifespan and investment in projects aimed at earlier detection and intervention.
Among the initiatives announced, the Advanced Research Projects Agency for Health (ARPA-H) will provide up to $41 million to Mass General Brigham researchers to lead a multi-institutional Alzheimer’s platform trial. The trial is intended to test drugs approved for other conditions for possible use in Alzheimer’s, along with supplements, plant-derived products and other compounds. ARPA-H will also award $2.75 million to the University of California, San Francisco to complement research focused on sleep-related risks and early protein dysfunction.
The FDA also launched an Alzheimer’s Prevention Accelerator within its Neuroscience Advancement and Innovation Nexus program. HHS described additional work on dementia screening and training, behavioral health and crisis-response resources, public-health approaches, diagnostic delays and the economic burden of dementia. The Administration for Community Living will expand brain-health resources and training for elder-justice professionals, including lawyers and social workers. Other efforts include reviewing prevention evidence and testing a lifestyle intervention for people with mild cognitive impairment.
Research, Prevention and Care Priorities
The update links a national policy framework to a set of specific federal programs, from testing possible treatments to expanding professional training and caregiver resources. The platform trial is designed to examine candidates that already have approval for other conditions as well as supplements and other compounds. Its announcement does not establish that any of those candidates prevent or treat Alzheimer’s; their effects would need to be evaluated through research.
The range of initiatives also reflects that dementia policy extends beyond drug development. Earlier detection, care services, support for caregivers and efforts to address abuse and financial exploitation can affect people living with cognitive decline and their families. HHS has outlined areas of work, but the announcement does not provide outcome data showing how the revised plan will change access to diagnosis, treatment or support.
dementia caregiver activity books for seniors
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Six Goals to Four
The National Plan to Address Alzheimer’s Disease and Related Dementias is the federal strategy being revised in this announcement. HHS said the update shifts the plan’s emphasis toward prevention, earlier detection and faster development of diagnostics and treatments. The new structure consolidates the prior six historical goals into four broader priorities, including dementia care and caregiver support.
The initiatives named by HHS involve several agencies and institutions rather than a single program. ARPA-H’s proposed funding supports research projects; the FDA’s accelerator is part of its NAIN program; and the Administration for Community Living is expanding resources and training for professionals working with older adults. The Alzheimer’s Association welcomed the administration’s stated focus on innovation and care, while also calling for access to scientific advances.
“Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments.”
— HHS Secretary Robert F. Kennedy Jr., in an HHS news release
large display dementia-friendly digital clock calendar
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Funding, Timelines and Access
The announcement does not specify when the initiatives will begin, how long they will run, or when results from the platform trial or other research might be available. ARPA-H described its investment as “up to” stated amounts; the material does not give a full breakdown of how much will ultimately be spent across the projects or their milestones.
It is also not yet clear how the four goals will be measured, what resources will be devoted to each, or how the plan will affect access to screening, diagnosis, treatment and caregiver services. The trial is intended to test possible therapies, but no findings were reported. The Alzheimer’s Association called on Congress to pass the bipartisan ASAP (Alzheimer’s Screening and Prevention) Act to help Medicare beneficiaries benefit from advances in blood-based biomarker testing; the supplied report does not establish whether or when Congress will act.
Alzheimer's caregiver communication and activity guide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial and Program Milestones
The next developments to watch are the launch and design details of the Mass General Brigham-led platform trial, including which candidates are tested and when researchers expect to report results. Further information about awards, schedules and progress from ARPA-H and UCSF would help clarify how the announced research funding is being used.
HHS agencies will also need to provide details on implementation of the FDA accelerator, expanded elder-justice training and the other screening, care and public-health initiatives. The administration has announced the revised priorities, but the source material does not give a reporting calendar or specific measures for evaluating the plan. Congressional consideration of the ASAP Act remains a separate potential development identified by the Alzheimer’s Association.
brain health puzzle books for older adults
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What changed in the national Alzheimer’s and dementia plan?
HHS replaced six historical goals with four, focused on risk reduction, preventing and treating Alzheimer’s and dementia, dementia care, and caregiver support.
How much research funding did ARPA-H announce?
ARPA-H announced a collective investment of up to $48.8 million. This includes up to $41 million for a Mass General Brigham-led platform trial and a $2.75 million award to support research at UCSF.
What will the platform trial test?
The planned trial will test drugs approved for other conditions for possible use in Alzheimer’s, as well as supplements, plant-derived products and other compounds. The announcement provides no trial results or evidence that these candidates work for Alzheimer’s.
What is the FDA’s Alzheimer’s Prevention Accelerator?
It is a new FDA initiative within the Neuroscience Advancement and Innovation Nexus, intended to foster approaches to prevent or delay cognitive decline due to Alzheimer’s.
When will the plan’s results be known?
HHS did not provide a timeline for research findings or a schedule for evaluating the plan. Trial milestones and implementation details have not been specified in the source report.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
